argenx

business targets illustration
Biotech

Argenx's $1.5B pact to turn macrocyclic peptides to new targets

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Unnatural Products.
James Waldron Jul 1, 2025 8:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Leo's eczema prospect hits primary endpoint in phase 2b

May 9, 2025 7:30am
target reach ladder climb meet win beat competition

J&J's phase 2 Sjögren's data support FcRn strategy

Jun 17, 2024 8:47am
graphic image of a cube with an arrow nailing the bullseye

Roivant FcRn inhibitor avoids cholesterol problem, shares spike

Sep 26, 2023 10:56am
A business window with a sign that says welcome we are open

Metrodora opens neuroimmune research center in Salt Lake City

Apr 19, 2023 11:11am
business deal strategy partnership gears plan

Argenx, Genmab join forces to expand into new therapeutic areas

Apr 17, 2023 6:20am